Dysfunction of the PI3 kinase/Rap1/integrin IIb 3 pathway underlies ex vivo platelet hypoactivity in essential thrombocythemia

School of Physiology and Pharmacology, School of Medical Sciences, University of Bristol, Bristol, United Kingdom
Blood (Impact Factor: 10.45). 12/2012; 121(7). DOI: 10.1182/blood-2012-05-431288
Source: PubMed


Patients with myeloproliferative disorders (MPD) such as essential thrombocythemia (ET) have increased risk of thrombosis and bleeding, which are major sources of morbidity and mortality. Most MPD patients have a gain of function mutation in Janus kinase 2 (JAK2V617F), but little is known how JAK2V617F affects platelet function. Here, we demonstrate that platelets from ET patients have impaired SFLLRN-mediated fibrinogen binding and have lost the potentiating effect of thrombopoietin (which couples to JAK2) on this pathway. In contrast, SFLLRN-mediated P-selectin expression, ATP secretion, phosphorylation of the PKC substrate pleckstrin and Ca(2+) mobilisation were unaffected in JAK2V617F positive platelets. In addition, thrombopoietin-mediated JAK2 phosphorylation was unchanged, suggesting that signalling pathways activated downstream of JAK2 are impaired. Indeed, we found that platelets from JAK2V617F positive ET patients have significantly reduced phosphorylation of the PI3 kinase substrate Akt, and have reduced activation of Rap1 in response to thrombopoietin, IGF-1, ADP, SFLLRN and thrombin. This effect was independent of Giα P2Y12 purinergic receptor function as ADP-mediated inhibition of VASP phosphorylation was unchanged. These results demonstrate that the PI3 kinase/Rap1 pathway is intrinsically impaired in platelets from JAK2V617F positive ET patients, resulting in diminished thrombin and thrombopoietin-mediated integrin α(IIb)β(3) activation.

Download full-text


Available from: Joshua Savage, May 20, 2015
  • Source
    • "It has been evidenced that the process of platelet aggregation and thrombus formation was related to the P-selectin secretion and GP IIb/IIIa activation which was also cross-linked Akt activation [24, 25]. Our current results provided the certainly evidence that ALA can reduce P-selectin secretion and GP IIb/IIIa expression obviously. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background The current study was to evaluate the anti-thrombotic effect of alpha-linolenic acid (ALA) which was isolated and purified from Jiaomu in vivo. Methods The seeds were crushed and subsequently subjected to saponification, acid hydrolysis, gradient freezing, urea inclusion and complexation of silver nitrate to obtain the unsaturated fatty acids. The chemical characteristics of isolated ALA were validated by 1HNMR, 13CNMR and mass spectrometry, and then the anti-thrombotic effect of ALA and its mixture with linoleic acid (1:1) were evaluated in the following experiments. Results The alpha-linolenic acid was isolated and purified from Jiaomu through our newly established methods. ALA and its mixture with linoleic acid can prolong the hemorrhage and coagulation time as well as enhanced the survival rate of mice subjected to collagen-adrenaline induced thrombosis. In addition, the thrombosis on A-V bypass and platelet aggregation of rats will be reduced after treated with ALA or its mixture, and the expression level of Akt and PI3K protein decreased 26% and 31%, respectively. Conclusions We designed and optimized a very simple and high-yield procedure to isolate ALA and linoleic acid mixture from seeds of Zanthoxylum bungeanum Maxim and demonstrated that such mixture can obtain a good anti-thrombotic effect through the modulation of PI3K/Akt signaling.
    Full-text · Article · Sep 2014 · BMC Complementary and Alternative Medicine
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The principal morbidity and mortality in patients with essential thrombocythaemia (ET) and polycythaemia vera (PV) stems from thrombotic events. Most patients with ET/PV harbor a JAK2V617F mutation but its role in the thrombotic diathesis remains obscure. Platelet function studies in patients are difficult to interpret because of inter-individual heterogeneity, reflecting variations in the proportion of platelets derived from the malignant clone, differences in the presence of additional mutations and the effects of medical treatments. To circumvent these issues we have studied a JAK2V617F knock-in mouse model of ET in which all megakaryocytes and platelets express JAK2V617F at a physiological level, equivalent to that present in human ET patients. We show that, in addition to increased differentiation, JAK2V617F positive megakaryocytes display greater migratory ability and proplatelet formation. We demonstrate in a range of assays that platelet reactivity to agonists is enhanced, with a concomitant increase in platelet aggregation in vitro and a reduced duration of bleeding in vivo. These data suggest that JAK2V617F leads to intrinsic changes in both megakaryocyte and platelet biology beyond an increase in cell number. In support of this hypothesis, we identify multiple differentially expressed genes in JAK2V617F megakaryocytes that may underlie the observed biological differences.
    Full-text · Article · Oct 2013 · Blood
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Rapamycin, an inhibitor of mammalian target of rapamycin complex-1 (mTORC1), reduces platelet spreading, thrombus stability and clot retraction. Despite an important role of mTORC1 in platelet function, little is known about how it is regulated. The objective of this study was to determine the signalling pathways that regulate mTORC1 in human platelets.MethodsmTORC1 activation was assessed by measuring the phosphorylation of its downstream substrate p70S6K. ResultsThrombin or the PKC activator PMA stimulated activation of mTORC1 in a PKC-dependent, Akt-independent manner which correlated with phosphorylation of TSC2 (Ser939 and Thr1462). In contrast, IGF-1-stimulated TSC2 phosphorylation was completely dependent on PI3kinase/Akt, but did not result in any detectable mTORC1 activation. Early (Ser939 and Thr1462) and late (Thr1462) TSC2 phosphorylation in response to thrombin were directly PKC dependent, whereas later TSC2 (Ser939) and p70S6K phosphorylation were largely dependent on paracrine signalling through P2Y12. PKC-mediated ADP secretion was essential for thrombin-stimulated mTORC1 activation, as (i) ADP rescued p70S6K phosphorylation in the presence of a PKC inhibitor and (ii) P2Y12 antagonism prevented thrombin-mediated mTORC1 activation. Rescue of mTORC1 activation with exogenous ADP was completely dependent on the Src family kinases, but independent of PI3kinase/Akt. Interestingly, although inhibition of Src blocked the ADP rescue, it had little effect on thrombin-stimulated p70S6K phosphorylation under conditions where PKC was not inhibited. Conclusion These results demonstrate that thrombin activates the mTORC1 pathway in human platelets through PKC-mediated ADP secretion and subsequent activation of P2Y12, in a manner largely independent of the canonical PI3kinase/Akt pathway.This article is protected by copyright. All rights reserved.
    Full-text · Article · Mar 2014 · Journal of Thrombosis and Haemostasis
Show more